These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7066802)

  • 1. Decreased elimination of theophylline after influenza vaccination.
    Goldstein RS; Cheung OT; Seguin R; Lobley G; Johnson AC
    Can Med Assoc J; 1982 Mar; 126(5):470. PubMed ID: 7066802
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased elimination of theophylline after influenza vaccination.
    Renton KW; Gray JD; Hall RI
    Can Med Assoc J; 1980 Aug; 123(4):288-90. PubMed ID: 7260771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum theophylline levels after influenza vaccination.
    Britton L; Ruben FL
    Can Med Assoc J; 1982 Jun; 126(12):1375. PubMed ID: 7083092
    [No Abstract]   [Full Text] [Related]  

  • 4. Influenza vaccination and theophylline pharmacokinetics in patients with chronic obstructive lung disease.
    Stults BM; Hashisaki PA
    West J Med; 1983 Nov; 139(5):651-4. PubMed ID: 6659488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism.
    Winstanley PA; Tjia J; Back DJ; Hobson D; Breckenridge AM
    Br J Clin Pharmacol; 1985 Jul; 20(1):47-53. PubMed ID: 4027135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroconversion after influenza vaccination in patients with lung cancer.
    Anderson H; Petrie K; Berrisford C; Charlett A; Thatcher N; Zambon M
    Br J Cancer; 1999 Apr; 80(1-2):219-20. PubMed ID: 10389999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza and pneumococcal vaccination levels among persons aged > or = 65 years--United States, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(45):1019-24. PubMed ID: 12458918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2009 Aug; 60(8):2438-47. PubMed ID: 19644961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States.
    Ajani UA; Ford ES; Mokdad AH
    Am Heart J; 2005 Feb; 149(2):254-9. PubMed ID: 15846262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of influenza virus vaccine on hepatic drug metabolism.
    Meredith CG; Christian CD; Johnson RF; Troxell R; Davis GL; Schenker S
    Clin Pharmacol Ther; 1985 Apr; 37(4):396-401. PubMed ID: 3979001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Note on interactions involving theophylline kinetics.
    Harless GR
    Drug Intell Clin Pharm; 1983 Feb; 17(2):132-3. PubMed ID: 6825570
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of trivalent influenza vaccine on serum theophylline levels.
    Fischer RG; Booth BH; Mitchell DQ; Kibbe AH
    Can Med Assoc J; 1982 Jun; 126(11):1312-3. PubMed ID: 7074460
    [No Abstract]   [Full Text] [Related]  

  • 13. Deaths following influenza vaccination--background mortality or causal connection?
    Kokia ES; Silverman BG; Green M; Kedem H; Guindy M; Shemer J
    Vaccine; 2007 Dec; 25(51):8557-61. PubMed ID: 18006121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse reactions to simultaneous influenza and pneumococcal vaccination.
    McCue JD
    J Fam Pract; 1981 Aug; 13(2):175-7. PubMed ID: 7252446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation.
    Posthouwer D; Voorbij HA; Grobbee DE; Numans ME; van der Bom JG
    Vaccine; 2004 Dec; 23(3):362-5. PubMed ID: 15530681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccination among Canadians with chronic respiratory disease.
    Vozoris NT; Lougheed MD
    Respir Med; 2009 Jan; 103(1):50-8. PubMed ID: 18818066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic vasculitis following influenza vaccination--report of 3 cases and literature review.
    Mader R; Narendran A; Lewtas J; Bykerk V; Goodman RC; Dickson JR; Keystone EC
    J Rheumatol; 1993 Aug; 20(8):1429-31. PubMed ID: 8230034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal and influenza vaccination levels among adults aged > or = 65 years--United States, 1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Oct; 45(40):853-9. PubMed ID: 8927004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.